|
1
|
Maplanka C: Gallbladder cancer, treatment
failure and relapses: The peritoneum in gallbladder cancer. J
Gastrointest Cancer. 45:245–255. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Dutta U, Bush N, Kalsi D, Popli P and
Kapoor VK: Epidemiology of gallbladder cancer in India. Chin Clin
Oncol. 8(33)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Valle JW, Borbath I, Khan SA, Huguet F,
Gruenberger T and Arnold D: ESMO Guidelines Committee. Biliary
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 27 (Suppl 5):v28–v37. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Wang H, Ling W and Luo Y:
Contrast-enhanced ultrasound findings of gallbladder adenocarcinoma
with sarcomatoid carcinoma accompanied by intrahepatic metastasis:
A case report and literature review. Medicine (Baltimore).
97(e10773)2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Oh J, Steel M, Conklin C and
Aquino-Parsons C: Metastatic gallbladder adenocarcinoma to the
endometrium: A case report and review of literature. Cureus.
11(e5258)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
National Comprehensive Cancer Network.
Hepatobilliary Cancers (Version 2.2019). (2019). Accessed: Jannuary
31, 2020: https://www.nccn.org/professionals/physician_gls/PDF/hepato-biliary.pdf.
|
|
7
|
André T, Tournigand C, Rosmorduc O,
Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun
L, Houry S, et al: Gemcitabine combined with oxaliplatin (GEMOX) in
advanced biliary tract adenocarcinoma: A GERCOR study. Ann Oncol.
15:1339–1343. 2004.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhu AX, Meyerhardt JA, Blaszkowsky LS,
Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan
JA, Enzinger PC, et al: Efficacy and safety of gemcitabine,
oxaliplatin, and bevacizumab in advanced biliary-tract cancers and
correlation of changes in 18-fluorodeoxyglucose PET with clinical
outcome: A phase 2 study. Lancet Oncol. 11:48–54. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Keating GM: Bevacizumab: A review of its
use in advanced cancer. Drugs. 74:1891–1925. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Uji M, Mizuno T, Ebata T, Sugawara G,
Igami T, Uehara K and Nagino M: A case of advanced intrahepatic
cholangiocarcinoma accidentally, but successfully, treated with
capecitabine plus oxaliplatin (CAPOX) therapy combined with
bevacizumab: A case report. Surg Case Rep. 2(63)2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sacchetti F, Ardito F, Vecchio FM and
Giuliante F: Exceptional long-term survivor (12 years) with
metastatic gallbladder cancer. Glob Surg 5, 2019.
|
|
12
|
Kanthan R, Senger JL, Ahmed S and Kanthan
SC: Gallbladder cancer in the 21st century. J Oncol.
2015(967472)2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Caldow Pilgrim CH, Groeschl RT, Quebbeman
EJ and Gamblin TC: Recent advances in systemic therapies and
radiotherapy for gallbladder cancer. Surg Oncol. 22:61–67.
2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Athauda A, Fong C, Lau DK, Javle M,
Abou-Alfa GK, Morizane C, Steward K and Chau I: Broadening the
therapeutic horizon of advanced biliary tract cancer through
molecular characterisation. Cancer Treat Rev.
86(101998)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Zhang W, Zhou H, Wang Y, Zhang Z, Cao G,
Song T, Zhang T and Li Q: Systemic treatment of advanced or
recurrent biliary tract cancer. Biosci Trends. 14:328–341.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lim KS, Peters CC, Kow A and Tan CH: The
varying faces of gall bladder carcinoma: Pictorial essay. Acta
Radiol. 53:494–500. 2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yoshimitsu K, Nishihara Y, Okamoto D,
Ushijima Y, Nishie A, Yamaguchi K, Taketomi A and Honda H: Magnetic
resonance differentiation between T2 and T1 gallbladder carcinoma:
Significance of subserosal enhancement on the delayed phase dynamic
study. Magn Reson Imaging. 30:854–859. 2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Harder J, Kummer O, Olschewski M, Otto F,
Blum HE and Opitz O: Prognostic relevance of carbohydrate antigen
19-9 levels in patients with advanced biliary tract cancer. Cancer
Epidemiol Biomarkers Prev. 16:2097–2100. 2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al: Cisplatin plus gemcitabine versus gemcitabine for
biliary tract cancer. N Engl J Med. 362:1273–1281. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Fiteni F, Nguyen T, Vernerey D, Paillard
MJ, Kim S, Demarchi M, Fein F, Borg C, Bonnetain F and Pivot X:
Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment
of advanced biliary tract cancer: A systematic review. Cancer Med.
3:1502–1511. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
21
|
Malka D, Fartoux L, Rousseau V, Trarbach
T, Boucher E, De La Fouchardiere C, Faivre SJ, Viret F, Blanc JF,
Assenat E, et al: Gemcitabine and oxaliplatin (GEMOX) alone or in
combination with cetuximab as first-line treatment for advanced
biliary cancer: Final analysis of a randomized phase II trial
(BINGO). J Clin Oncol. 30(4032)2012.
|
|
22
|
Gruenberger B, Schueller J, Heubrandtner
U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S and
Gruenberger T: Cetuximab, gemcitabine, and oxaliplatin in patients
with unresectable advanced or metastatic biliary tract cancer: A
phase 2 study. Lancet Oncol. 11:1142–1148. 2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Safran H, Miner T, Resnick M, Dipetrillo
T, McNulty B, Evans D, Joseph P, Plette A, Millis R, Sears D, et
al: Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: A
phase I study for advanced pancreaticobiliary cancer. Am J Clin
Oncol. 31:140–144. 2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Letelier P, Garcia P, Leal P, Ili C,
Buchegger K, Riquelme I, Sandoval A, Tapia O and Roa JC:
Immunohistochemical expression of vascular endothelial growth
factor A in advanced gallbladder carcinoma. Appl Immunohistochem
Mol Morphol. 22:530–536. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Intas Launches Bevatas (bevacizumab) in
India. [cited 09 Nov 2020]. Available from urihttps://www.bigmoleculewatch.com/2017/10/17/intas-launches-bevatas-bevacizumab-india/?highlight=bevatassimplehttps://www.bigmoleculewatch.com/2017/10/17/intas-launches-bevatas-bevacizumab-india/?highlight=bevatas.
|
|
26
|
Young H, Baum R, Cremerius U, Herholz K,
Hoekstra O, Lammertsma AA, Pruim J and Price P: Measurement of
clinical and subclinical tumour response using
[18F]-fluorodeoxyglucose and positron emission
tomography: Review and 1999 EORTC recommendations. European
Organization for Research and Treatment of Cancer (EORTC) PET Study
Group. Eur J Cancer. 35:1773–1782. 1999.PubMed/NCBI View Article : Google Scholar
|
